Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMS 2026 | The role of patient preference in selecting treatment administration routes in multiple myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the importance of patient preference and shared decision-making when selecting treatment administration routes in multiple myeloma. He highlights the convenience and potential benefits of subcutaneous isatuximab delivered via an on-body injector (OBI), drawing parallels with subcutaneous daratumumab. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

In the new era of multiple myeloma we have many opportunities and I think that this is particularly important because the patient can be part of the shared decision making and I think that the idea of having a possibility of administration that is really fast, really safe and really comfortable can be something that the patient should know in order to decide and in order to participate in the decision of the treatment...

In the new era of multiple myeloma we have many opportunities and I think that this is particularly important because the patient can be part of the shared decision making and I think that the idea of having a possibility of administration that is really fast, really safe and really comfortable can be something that the patient should know in order to decide and in order to participate in the decision of the treatment. I think that this comes from IRAKLIA and IZALCO but can potentially can be applied to all these isatuximab-based regimens, and I hope in the next future also to other subcutaneous drugs, some tools are starting to be explored. And I think that in the next future, thanks to these tools like OBI or body injector, maybe we can drive a lot of patients at home and maybe we can really make myeloma a chronic disease in which the patients come only rarely to the hospital. And this will be in some way a new era for not only the patient but also for the optimization of staff of the hospitals and also for caregivers. I think that OBI is a great revolution, is a great game changer in the therapeutic panorama of multiple myeloma and I think that the best has to come in the future with positioning and potentially new opportunities that decentralize the patient also in their domestic setting.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.